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Abstract
Background: A reduction in skeletal muscle performance measured 
by handgrip strength is common in heart failure. No trial has inves-
tigated the role of cardiac resynchronization therapy, which leads to 
improvements in cardiac performance, on the function of skeletal 
muscle in patients with heart failure.
Methods: Nineteen patients were recruited, 18 male, age 69 ± 8 
years, New York Heart Association class II-IV, QRS duration 173 ± 
21 ms and left ventricular ejection fraction 26±8%. Handgrip strength 
was measured at baseline before, and 6 and 12 months, following car-
diac resynchronization therapy. Response was assessed using quality 
of life questionnaire, 6-minute walk distance, left ventricular end-
diastolic volume, and cardiopulmonary exercise testing at the same 
time points.
Results: Fourteen patients were identified as responders, demonstrat-
ing significant improvements in all four markers of response. There 
was no significant difference at baseline in left or right handgrip 
strength between responders and non-responders. Compared to base-
line, handgrip strength significantly increased in responders during 
follow-up, left (34.4 ± 11.4 to 40.3 ± 11.3 kgf, P < 0.001) and right 
(35.7 ± 12.5 to 42.2 ± 11.5 kgf, P < 0.001) at 12 months. No such 
improvement was seen in non-responders.
Conclusions: This study demonstrates that positive response to car-
diac resynchronization therapy is associated with significant gains in 
handgrip strength, suggesting that cardiac resynchronization therapy 
may indirectly lead to secondary gains in skeletal muscle function.
Keywords: Cardiac resynchronization therapy; Heart failure; Hand-
grip strength
Introduction
Heart failure (HF) is not a single organ disease but rather a 
multifaceted syndrome, which can result in psychological, 
musculoskeletal, hematological, pulmonary, endocrine, en-
dothelial, renal and hepatic impairment [1]. The muscle hy-
pothesis of HF proposed that “exercise performance in HF 
patients is predominantly limited by skeletal muscle and less 
by the performance of cardiac muscle” [2]. Handgrip strength 
(HGS) is the maximum force that can be generated by the hand 
and forearm musculature during a single isometric contraction 
and as such is a measure of skeletal muscle performance. HGS 
correlates well with overall body strength, is used as a marker 
of exercise capacity, general health and nutritional status and 
deteriorates with aging and chronic disease. In HF, HGS can 
be used to stratify patients according to functional class, peak 
VO2 and is an independent predictor of survival [3-7]. Previ-
ous clinical trials have shown pharmacotherapies commonly 
used in HF, such as angiotensin converting enzyme (ACE) in-
hibitors, to preserve lean body weight but not affect skeletal 
muscle function [8, 9].
Cardiac resynchronization therapy (CRT) is a widely used 
treatment in HF; it improves the hearts pumping efficiency by 
restoring synchronous contraction of the atria and ventricles. 
Benefits include improved quality of life and exercise capac-
ity and reduced hospitalization and mortality [10]. Despite 
meeting strict implantation criteria, only two-thirds of patients 
respond to this complex device therapy and it still remains un-
clear as to why this is the case [11].
To date, no trial has investigated the role of CRT influ-
encing skeletal muscle performance, such as measuring HGS, 
presenting a means of differentiating between responders and 
non-responders, at baseline and during follow-up. If HGS, a 
simple, inexpensive and reliable test could be used to differ-
entiate likely responders from non-responders at baseline pre-
CRT implantation, then this would be invaluable to clinicians, 
patient groups and researchers alike. Furthermore, any differ-
ences in HGS as a result of CRT identified during follow-up 
would further refine current understanding of response to CRT 
and possible reasons underlying non-response.
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Methods
Ethics approval and consent to participate
All patients gave fully informed written consent to take part 
in the project. The project was conducted in compliance with 
the principles of the Declaration of Helsinki (October 2008), 
the principles of Good Clinical Practice (GCP) and all of the 
applicable regulatory requirements. The project was approved 
by the National Research Ethics Service (NRES) number 10/
H0802/71.
Recruitment
Patients were screened for eligibility by a physician and a ded-
icated clinical research fellow. Nineteen patients who received 
CRT based on current clinical criteria used at Sheffield Teach-
ing Hospitals (STH) NHS Trust were recruited for this study, 
i.e., patients with an ejection fraction < 35%, a QRSd > 120 
ms, NYHA functional class II-IV and optimal medical therapy. 
No patients had a history of wrist or hand arthritis and patients 
were examined specifically prior to starting the study.
Study design
The study was a prospective cohort study using an opportunity 
sample. All patients recruited to the study had their HGS as-
sessed at baseline, 6 and at 12 months (± 2 weeks) post-CRT 
implantation. At the same time points, they underwent echo-
cardiography and cardiopulmonary exercise testing (CPET) to 
measure their peak VO2 and completed the Minnesota Living 
With Heart Failure Questionnaire (MLWHFQ). At 6 weeks 
after CRT implantation, all patients were referred for routine 
echocardiography-guided CRT optimization, using the itera-
tive method to optimize atrio-ventricular delay and the aortic 
velocity time integral method for the inter-ventricular delay.
Assessment of grip strength
HGS was measured at baseline, 6 and 12 months using a single 
protocol; patients were asked to perform three maximal trials 
with each hand using a Jamar analogue dynamometer on the 
morning of testing. The patients were all positioned accord-
ing to the American Society of Hand Therapists (ASHT) guid-
ance [11]. Standardized verbal instructions and encouragement 
were used as recommended by Mathiowetz et al (1984) [12]. 
The investigator carrying out HGS measurement was blinded 
to markers of response to CRT. The analogue Jamar dynamom-
eter used to measure HGS had excellent test-retest (r = 0.88 
- 0.93) and inter-rater (r = 0.99) reliability [12]. Measurement 
of HGS was known to be sensitive to a range of factors such 
as patient encouragement, time of day, posture, the position of 
the upper limb joints (shoulder, elbow, and wrist) and even the 
position of the dynamometer handle itself, hence it was essen-
tial to use a standardized approach [13]. There was a learning 
effect with using the dynamometer and in an attempt to negate 
this, the best of three attempts for both right and left hands was 
used.
Assessment of response to CRT
A positive response to CRT was defined a priori by the authors, 
as a significant improvement in all of four different outcome 
measures, a > 1 mL/kg/min increase in peak VO2, a > 15% 
reduction in left ventricular end-diastolic volume (LVEDV), 
a > 10% increase in 6-min walk distance (6MWD) and a > 10 
point reduction in symptoms as measured by the MLWHFQ 
quality of life (QoL) questionnaire.
CPET consisted of a ramp protocol on a static bicycle er-
gometer to measure peak VO2 supervised by a senior pulmo-
nary physiologist. Peak VO2 was the highest measure of VO2 
attained, but not necessarily that, which would be ultimately 
attainable and had been shown to improve significantly in re-
sponders to CRT.
LVEDV was calculated using the modified Simpson’s 
rule of stack discs using apical two- and four-chamber views 
by two-dimensional echocardiography General Electric (GE 
Healthcare, Princeton, NJ) Vivid 7 ultrasound machine, as-
sessed by senior echocardiographers.
The 6-min walk test (6MWT) measured the distance 
walked at a normal pace on a flat, hard, even surface in 6 min, 
the 6MWD.
The MLWHFQ was a validated and well-tested question-
naire assessing the impact of HF on QoL, and specifically it 
asked questions on domains relating to both psychological and 
physiological factors, including questions on the side-effects 
of treatments, hospital admissions, symptoms, mood, sex-life 
and appetite. The investigators administered the questionnaire.
Statistical analysis
Statistical analysis was performed using SPSS software (ver-
sion 21.0, SPSS Inc., Chicago, IL, USA). Assessment of data 
for normality was carried out using both visual assessment of 
the data and Shapiro-Wilks test. Categorical data were ana-
lyzed using a two-tailed Fisher’s exact test. Parametric data are 
given in terms of the mean ± SD. Comparison of data between 
groups at baseline was performed using an unpaired two-tailed 
Student’s t-test. Comparison of data within groups during fol-
low was performed using one-way ANOVA with repeated 
measures. Correlations were analyzed with the Pearson’s cor-
relation coefficient. P values of < 0.05 were considered sig-
nificant.
Results
Nineteen patients were included in the study. The baseline pa-
tient characteristics are shown in Table 1. As can be seen, all 
patients had similarly impaired LV function at baseline and a 
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prolonged QRS duration. Furthermore, there were no statisti-
cally significant differences between the baseline measures of 
response, such as LVEDV, peak VO2, 6MWD or MLWHFQ 
(Table 1).
Response to CRT
A positive response to CRT in the four criteria was observed in 
14 of the 19 patients after 12 months of CRT (Table 2).
A one-way ANOVA with repeated measures and Green-
house-Geisser correction determined that peak VO2 (F(1.27, 
13.9) = 9.26, P < 0.01), LVEDV (F(1.73, 17.3) = 6.73, P < 
0.01), MLWHFQ (F(1.97, 21.76) = 7.40, P < 0.01) and 6MWD 
(F(1.93, 21.03) = 22.67, P < 0.01) in responders was statis-
tically different between time points during follow-up. Post 
hoc analysis using the Bonferroni correction demonstrated 
responders had statistically significant differences between 
baseline and 6 months and baseline and 12 months in 6MWD 
(Fig. 1A), peak VO2 (Fig. 1B), MLWHFQ score (Fig. 1C) and 
LVEDV (Fig. 1D).
Non-responders failed to demonstrate a significant differ-
ence in any of these four markers between time points accord-
ing to a one-way ANOVA with repeated measures (Table 2 and 
Fig. 2A-D).
There was no significant difference in the workload (Watts) 
measured at peak VO2 at baseline between the responders and 
non-responders (91.2 ± 24.9 W and 93.2 ± 18.7 W, P = 0.29), 
using an unpaired Student’s t-test.
A one-way ANOVA with repeated measures that did not 
violate Mauchly’s test of sphericity determined that workload 
in responders was statistically different between time points in 
Table 1.  Baseline Characteristics of Responders and Non-Responders Pre-CRT Implantation
Responders (N = 14) Non-responders (N = 5) P value
Demographics
  Age (years) 68.4 9.8 71.8 4.2 0.53
  Gender (male) 13 93% 5 100% 0.99*
  Handedness (right) 14 100% 5 100% 0.99*
  Body mass index (kg/m2) 29.6 3.98 26.5 4.41 0.18
  Ischemic heart disease 8 57% 3 60% 0.99*
  Hypercholesterolemia 10 72% 4 80% 0.99*
  Hypertension 7 50% 2 40% 0.99*
  Chronic kidney disease 4 29% 4 80% 0.11*
  Diabetes 5 36% 1 20% 0.99*
ECG/echocardiography
  QRSd (ms) 163.0 22.8 155.5 20.9 0.55
  EF (%) 25.6 8.0 25.8 8.5 0.44
Medications
  ACEI/ARB 13 93% 5 100% 0.99*
  Beta-blocker 12 86% 5 100% 0.99*
  Loop diuretic 14 100% 5 100% 0.99*
  Spironolactone 9 64% 4 80% 0.99*
Markers of response
  6MWD (m) 374.0 112.8 337.0 144.7 0.23
  LVEDV (mL) 201.5 72.5 159.0 80.8 0.37
  MLWHFQ 44.4 22.9 52.8 22.7 0.33
  Peak VO2 (mL/kg/min) 12.5 1.6 13.9 2.7 0.25
Hand grip strength (kgf)
  Left 34.4 11.4 33.0 5.3 0.42
  Right 35.7 12.5 31.2 12.2 0.25
Mean or number given in right hand column and % or SD given in left hand column. ^Comparisons between 
groups analyzed using two-tailed unpaired Student’s t-test unless categorical data (*) compared using Fisher’s 
exact test. ACE: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CRT: cardiac re-
synchronization therapy; ECG: electrocardiography; EF: ejection fraction; LVEDV: left ventricular end-diastolic 
volume; QRSd: QRS duration.
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(F(2, 22) = 4.45, P < 0.05) but not non-responders (F(2, 6) = 
0.91, P = 0.45). Post hoc analysis using pairwise comparisons 
in responders only revealed that workload approached statisti-
cal significance between baseline and 6 months and baseline 
and 12 months (Fig. 3), but not 6 and 12 months (data not 
shown).
Hand grip strength
There were no statistically significant differences between the 
HGS of responders and non-responders at baseline (Table 1). 
There were also no statistically significant differences in HGS 
in responders and non-responders between the left and right 
hands (data not shown).
A one-way ANOVA with repeated measures and Green-
house-Geisser correction determined mean HGS in respond-
ers was statistically different between time points in the left 
(F(1.77, 17.71) = 21.03, P < 0.001) and the right (F(1.36, 
13.58) = 16.03, P < 0.01) hand. Post hoc tests using the Bon-
ferroni correction revealed that HGS increased statistically 
significantly between baseline and 6 months and baseline and 
12 months, but not 6 and 12 months (data not shown), in both 
hands (Table 3 and Fig. 4A and B).
A one-way ANOVA with repeated measures and Green-
house-Geisser correction determined that there were no statis-
Table 2.  Markers of Response at 0 (Baseline), 6 and 12 Months Follow-Up in Responders and Non-Responders
Markers of response Baseline, mean ± SD
6 months, 
mean ± SD
12 months, 
mean ± SD
One-way ANOVA with repeated measures P value
Baseline vs. 6 months Baseline vs. 12 months
Responders (N = 14)
  6MWD (m) 374.0 ± 112.8 391.0 ± 108.1 418.1 ± 105.3 < 0.05 < 0.05
  LVEDV (mL) 175.1 ± 67.2 157.0 ± 77.3 121.3 ± 72.0 < 0.05 < 0.05
  MLWHFQ/105 44.4 ± 22.9 24.4 ± 19.1 24.1 ± 21.3 < 0.05 < 0.05
  Peak VO2 (mL/kg/min) 12.5 ± 1.6 14.1 ± 2.7 14.7 ± 1.5 < 0.05 < 0.01
Non-responders (N = 5)
  6MWD (m) 337.0 ± 144.7 279.2 ± 155.5 279.6 ± 113.8 0.34
  LVEDV (mL) 159.0 ± 80.8 172.4 ± 126.2 145.6 ± 88.8 0.63
  MLWHFQ/105 52.8 ± 22.7 37.0 ± 20.6 36.4 ± 26.7 0.31
  Peak VO2 (mL/kg/min) 13.9 ± 2.7 11.5 ± 4.1 12.8 ± 3.9 0.21
LVEDV: left ventricular end-diastolic volume; MLWHFQ: Minnesota Living With Heart Failure Questionnaire; 6MWD: 6-minute walk distance.
Figure 1. The markers of response to cardiac resynchronization therapy, at time zero (baseline) before implantation, 6 and 12 
months following CRT implantation in responders (white): (A) 6-minute walk distance (6MWD); (B) peak VO2; (C) Minnesota 
Living With Heart Failure Questionnaire (MLWHFQ) score; (D) left ventricular end-diastolic volume (LVEDV). Differences in data 
from baseline to 6 and 12 months compared using one-way ANOVA with repeated measures. 
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tical differences between time points in the left (F(1.05, 4.22) 
= 1.29, P= 0.30) or right (F(1.12, 4.49) = 0.24, P = 0.66) hand 
(Table 3 and Fig. 4A and B) of non-responders.
Hand grip strength and CRT
Pearson’s correlation coefficient compared mean HGS with 
6MWD during follow-up over the 12 months (Fig. 5A and 
B, respectively), which proved significant in both the left (r = 
0.5160, n = 57, P < 0.001) and right (r = 0.6821, n = 57, P < 
0.001) hands.
Discussion
This study demonstrates, for the first time, a difference in HGS 
between responders and non-responders to CRT. At baseline, 
there is no significant difference in skeletal muscle function 
as measured by HGS. During follow-up however, there is a 
Figure 2. The markers of response to cardiac resynchronization therapy, at time zero (baseline) before implantation, 6 and 12 
months following CRT implantation in non-responders (black). (A) 6-minute walk distance (6MWD); (B) peak VO2; (C) Minnesota 
Living With Heart Failure Questionnaire (MLWHFQ) score; (D) left ventricular end-diastolic volume (LVEDV). Data during follow-
up compared using one-way ANOVA with repeated measures, with no significant difference. 
Figure 3. The peak workload (watts) measured during cardiopulmonary exercise testing in (A) responders (white) and (B) non-
responders (black) at time zero (baseline) before implantation and then 6 and 12 months following CRT, compared using one-way 
ANOVA with repeated measures. 
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significant improvement in HGS, and whilst non-significant, 
there is also a decline in HGS in the non-responders. This is 
despite no other significant difference in physical performance 
between the two groups at baseline. The improvement in HGS 
of 17-20% is similar to gains considered significant in other 
metrics of response such as LVEDV, peak VO2 or MLWHFQ. 
These results suggest that, by improving cardiac function in 
responders, CRT better enables patients to perform activities 
of daily living and so regain strength of the skeletal muscles. 
Furthermore, the positive correlation with 6MWD suggests 
that HGS is a real-world assessment of fitness; indeed at 12 
months follow-up, every 1.5 kgf increase in HGS correlated 
with a 10 m increase in 6WMD.
It is unlikely that CRT has a direct effect on skeletal mus-
cle other than a possible improvement of nutritive flow to the 
tissue, as a result of increased cardiac output [14]. To inves-
tigate possible mechanisms, skeletal muscle biopsy could be 
utilized to see what changes occur in skeletal muscle fiber dis-
tribution, metabolism, mitochondria and respiration, known to 
deteriorate in HF, improved as a consequence of CRT [15-20].
The assumption is made that gains in HGS reflect in-
creased muscle performance throughout the body, but it 
would be interesting to measure this in terms of function of 
other major muscle groups such as the quadriceps and knee 
extension strength [7]. Whilst there were no significant differ-
ences at baseline in any CPET measures, there were increases 
in peak VO2 and peak workload but not anaerobic threshold 
(data not shown). Whilst the changes in workload approached 
significance, unlike peak VO2, this suggests that response to 
CRT leads to specific gains in isometric strength in the upper 
limbs measured by HGS, and this may also translate into more 
generalized improvements in skeletal muscle function, demon-
strated by increase in workload in the lower limbs.
Sarcopenia is defined as the “age-associated loss of skel-
etal muscle mass and function” which is common in HF and 
independently associated with reduced exercise performance 
even when age, sex, functional class and co-morbidities are 
controlled for [21, 22]. However, in the absence of a measure 
of lean mass, this study investigated only differences in HGS, 
also known as dynapenia [23]. Whilst gains in HGS may be 
due to increased motor recruitment, myocyte hypertrophy may 
also be involved with CRT leading to a reversal of sarcopenia; 
measurement of lean mass by bioelectric impedance, dual en-
ergy X-ray absorptiometry or appendicular muscle volume by 
MRI would be needed to corroborate these findings and thus 
assess muscle mass and function, not just dynapenia. Clearly, 
Figure 4. Mean handgrip strength in the left (A) and right hand (B) at zero (baseline), 6 and 12 months following cardiac resyn-
chronization therapy (responders in solid gray line and non-responders in solid black line) with standard error bars. 
Table 3.  Handgrip Strength at 0 (Baseline), 6 and 12 Months Follow-Up in Responders and Non-Responders
Handgrip strength Baseline, mean ± SD
6 months, 
mean ± SD
12 months, 
mean ± SD
One way ANOVA with repeated measures P value
Baseline vs. 6 months Baseline vs. 12 months
Responders (N = 14)
  Left (kgf) 34.4 ± 11.4 39.7 ± 10.8 40.3 ± 11.3 < 0.01 < 0.001
  Right (kgf) 35.7 ± 12.5 39.8 ± 11.5 42.2 ± 11.2 < 0.01 < 0.001
Non-responders (N = 5)
  Left (kgf) 33.0 ± 5.3 27.6 ± 8.9 25.0 ± 11.7 0.30
  Right (kgf) 31.2 ± 12.2 30.8 ± 9.9 29.8 ± 8.1 0.66
kgf: kilograms of force; SD: standard deviation.
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measuring gross weight alone is fraught with error, as the HF 
condition leads to fluid retention and significant fluctuations in 
weight, but not muscle mass.
A possible confounder is serum albumin, an indicator of 
nutrition and associated with skeletal muscle performance 
[24-26]. Differences between the groups could reflect a more 
nutritionally replete/deplete cohort (as with HGS). However, 
serum albumin concentrations (mean and SD) were within 
normal limits (reference range 35 - 50 g/L) for all patients and 
no statistically significant difference was found during follow-
up in either group (data not shown). Serum albumin is influ-
enced by other co-morbidities such as liver and renal disease, 
all of which remained stable throughout the 12-month period 
of assessment. Furthermore, future research would be needed 
to ensure patients are consuming consistently 25 - 30 g high 
quality protein at breakfast, lunch and dinner, to provide suffi-
cient protein to effectively stimulate muscle protein anabolism 
and adequately control for this extraneous variable [27].
Importantly, there were no statistically significant differ-
ences at baseline between the two groups. Although there were 
some non-significant differences, this is likely to be due to the 
small sample size. This cohort was a small but homogenous 
sample, but there were no ethnic minorities and only one wom-
an and so it is difficult to translate the results to such popula-
tions. Whilst any improvement in HGS following a positive 
response to CRT implantation is correlation, not causation, 
there were no other significant clinical interventions during the 
12 months follow-up.
Defining response to CRT is problematic and subjective, 
for this reason the authors decided that any responder must 
demonstrate improvement in four completely different mark-
ers at certain thresholds, widely used in the literature, but not 
collectively [11, 28-30]. This was to ensure, as much as pos-
sible, that any response was true and not due to random vari-
ation, particularly in such a small patient population. Indeed, 
there was an improvement, albeit non-significant, in the ML-
WHFQ score in non-responders, but this is likely to be due to 
chance or placebo effect, especially as this was associated with 
no other response.
Taking into account both age and disease, this patient co-
hort has similar values of HGS to those reported in other CHF 
studies [5, 7]. The only intervention study examining HGS 
and HF demonstrated an increase in HGS of 2 kgf following 
a 3-month exercise programme [6]. The present CRT study 
demonstrates that similar gains at 12 months are found in CRT 
in patients who respond, on average 18% increase per hand. 
CRT allows patients to increase their own activity voluntarily, 
rather than as part of a specific exercise programme. It would 
be interesting to see if, as Belardinelli et al (2006) found with 
flow mediated dilatation (FMD) and endothelial dysfunction, 
further gains in HGS could be achieved by the adoption of an 
exercise programme and what, if any, effect this might have on 
other markers of response [31]. To date, there are no studies 
examining HGS in HF patients before and after routine cardiac 
rehabilitation. A recent study however demonstrated that ex-
ercise training in HF patients led to increases in muscle force 
and reductions in the levels of MuRF-1, a component of the 
ubiquitin-proteasome system involved in muscle proteolysis, 
which is increased in the skeletal muscle of patients with HF 
[32]. It would be interesting to see what impact positive re-
sponse CRT also had on such a biomarker.
There were no clinical events during 12 months follow-up, 
such as hospitalizations or deaths in either group, but in larger 
trials with longer follow-up, it would be interesting to see if 
such improvements in HGS were correlated with reductions in 
adverse events such as morbidity and mortality.
Conclusions
This study demonstrates for the first time that there are signifi-
cant improvements in the skeletal muscle performance of CRT 
responders, which correlates with 6MWD. This supports the 
notion that HGS is a simple, quick and inexpensive method of 
Figure 5. Correlation between handgrip strength (right and left) and 6-minute walk distance (6MWD) in the left (A) and right (B) 
hands both responders and non-responders, compared using Pearson’s correlation coefficient. 
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identifying responders to CRT. However, there are no signifi-
cant differences in HGS between responders and non-respond-
ers to CRT at baseline, and so based on this study, it cannot be 
used to identify responders.
This improvement in HGS may reflect the fact that HF is 
not purely a single organ disease and so such measures before 
and after initiating HF therapies should be considered to cor-
roborate improvement in symptoms and ensure this is not sim-
ply due to response bias, placebo or conformity. If larger stud-
ies demonstrated differences in HGS at baseline, the prospect 
of using a single simple test such as HGS to predict response 
to CRT remains a tantalizing possibility.
This was a small study in a homogenous population and 
so the findings will need replication in larger, diverse cohorts 
with such measurements at baseline and follow-up. Finally, 
further research is needed to investigate the mechanism be-
tween CRT and improved HGS.
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